Silicon Valley’s next risky self-optimization craze is unproven peptides

For many of these uses, the scientific backing is far weaker than that for GLP-1 drugs. Yet many users extrapolate from the proven success of GLP-1s to dozens of untested, unrelated peptides – often without randomized, placebo-controlled trials or independent, peer-reviewed publications. This dynamic blurs the line between legitimate pharmacology…

Read Entire Article